Functional imaging in Parkinson's disease.
Identifieur interne : 001516 ( PubMed/Checkpoint ); précédent : 001515; suivant : 001517Functional imaging in Parkinson's disease.
Auteurs : A. DagherSource :
- Seminars in neurology [ 0271-8235 ] ; 2001.
English descriptors
- KwdEn :
- Affect, Brain (diagnostic imaging), Brain (metabolism), Cognition, Dopamine (metabolism), Humans, Parkinson Disease (diagnosis), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson Disease (therapy), Parkinsonian Disorders (diagnosis), Parkinsonian Disorders (metabolism), Parkinsonian Disorders (therapy), Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , metabolism : Dopamine.
- diagnosis : Parkinson Disease, Parkinsonian Disorders.
- diagnostic imaging : Brain.
- metabolism : Brain, Parkinsonian Disorders.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- therapy : Parkinson Disease, Parkinsonian Disorders.
- Affect, Cognition, Humans, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon.
Abstract
This article reviews the applications of functional neuroimaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) to the diagnosis and treatment of Parkinson's disease (PD). PET measurements with [18F]deoxyglucose to measure glucose metabolism or with various markers of the pre- and postsynaptic dopamine systems may distinguish idiopathic PD from other conditions presenting with an akinetic-rigid state. Moreover, PET has been used to gain new insights into mechanisms of cell death and the role of heredity in Parkinson's disease. Finally, we discuss the use of functional neuroimaging to study the role of the basal ganglia in movement and cognition in PD.
PubMed: 11346022
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:11346022Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Functional imaging in Parkinson's disease.</title><author><name sortKey="Dagher, A" sort="Dagher, A" uniqKey="Dagher A" first="A" last="Dagher">A. Dagher</name><affiliation><nlm:affiliation>Montréal Neurological Institute, Quebec Canada.</nlm:affiliation><wicri:noCountry code="subField">Quebec Canada</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11346022</idno><idno type="pmid">11346022</idno><idno type="wicri:Area/PubMed/Corpus">001597</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001597</idno><idno type="wicri:Area/PubMed/Curation">001597</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001597</idno><idno type="wicri:Area/PubMed/Checkpoint">001597</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001597</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Functional imaging in Parkinson's disease.</title><author><name sortKey="Dagher, A" sort="Dagher, A" uniqKey="Dagher A" first="A" last="Dagher">A. Dagher</name><affiliation><nlm:affiliation>Montréal Neurological Institute, Quebec Canada.</nlm:affiliation><wicri:noCountry code="subField">Quebec Canada</wicri:noCountry></affiliation></author></analytic><series><title level="j">Seminars in neurology</title><idno type="ISSN">0271-8235</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Affect</term><term>Brain (diagnostic imaging)</term><term>Brain (metabolism)</term><term>Cognition</term><term>Dopamine (metabolism)</term><term>Humans</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Parkinson Disease (therapy)</term><term>Parkinsonian Disorders (diagnosis)</term><term>Parkinsonian Disorders (metabolism)</term><term>Parkinsonian Disorders (therapy)</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Affect</term><term>Cognition</term><term>Humans</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This article reviews the applications of functional neuroimaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) to the diagnosis and treatment of Parkinson's disease (PD). PET measurements with [18F]deoxyglucose to measure glucose metabolism or with various markers of the pre- and postsynaptic dopamine systems may distinguish idiopathic PD from other conditions presenting with an akinetic-rigid state. Moreover, PET has been used to gain new insights into mechanisms of cell death and the role of heredity in Parkinson's disease. Finally, we discuss the use of functional neuroimaging to study the role of the basal ganglia in movement and cognition in PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11346022</PMID><DateCreated><Year>2001</Year><Month>05</Month><Day>10</Day></DateCreated><DateCompleted><Year>2001</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-8235</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2001</Year></PubDate></JournalIssue><Title>Seminars in neurology</Title><ISOAbbreviation>Semin Neurol</ISOAbbreviation></Journal><ArticleTitle>Functional imaging in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>23-32</MedlinePgn></Pagination><Abstract><AbstractText>This article reviews the applications of functional neuroimaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) to the diagnosis and treatment of Parkinson's disease (PD). PET measurements with [18F]deoxyglucose to measure glucose metabolism or with various markers of the pre- and postsynaptic dopamine systems may distinguish idiopathic PD from other conditions presenting with an akinetic-rigid state. Moreover, PET has been used to gain new insights into mechanisms of cell death and the role of heredity in Parkinson's disease. Finally, we discuss the use of functional neuroimaging to study the role of the basal ganglia in movement and cognition in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dagher</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montréal Neurological Institute, Quebec Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Neurol</MedlineTA><NlmUniqueID>8111343</NlmUniqueID><ISSNLinking>0271-8235</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="Y">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="Y">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>77</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>5</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>5</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11346022</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Dagher, A" sort="Dagher, A" uniqKey="Dagher A" first="A" last="Dagher">A. Dagher</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001516 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001516 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:11346022
|texte= Functional imaging in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:11346022" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |